Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23983621 | 0.94 | MEN1 (0.32) | LIMK1MEN1LMNAMAPTMAPK1 | |
| SCHEMBL22652452 | 0.94 | CYP1A1 (0.34) | LIMK1CYP1A1CYP1B1MEN1LMNA | |
| SCHEMBL23129129 | 0.93 | MEN1 (0.33) | MEN1LMNAMAPTMAPK1RECQL | |
| SCHEMBL23983828 | 0.92 | TNKS (0.30) | — | |
| SCHEMBL23129422 | 0.91 | TNKS (0.30) | — | |
| SCHEMBL23984087 | 0.90 | — | — | |
| SCHEMBL22652453 | 0.89 | MEN1 (0.33) | LIMK1CYP1A1CYP1B1MEN1LMNA | |
| SCHEMBL23984048 | 0.88 | LIMK1 (0.33) | LIMK1 | |
| SCHEMBL23983839 | 0.88 | KDM4E (0.30) | L3MBTL1 | |
| SCHEMBL23983542 | 0.88 | KDM4E (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG CHEM, LTD. (KR) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | NR4A1, CYP1A1, ARNT | LIMK1 840/4885CYP1A1 2/4885CYP1B1 12/4885 |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | NR4A1, CYP1A1, ARNT | LIMK1 840/4885CYP1A1 2/4885CYP1B1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.